These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12440149)

  • 1. [Discovery and development of a new insulin sensitizing agent, pioglitazone].
    Sohda T; Kawamatsu Y; Fujita T; Meguro K; Ikeda H
    Yakugaku Zasshi; 2002 Nov; 122(11):909-18. PubMed ID: 12440149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Insulin resistance-reducing effect of a new thiazolidinedione derivative, pioglitazone].
    Ikeda H; Sugiyama Y
    Nihon Yakurigaku Zasshi; 2001 May; 117(5):335-42. PubMed ID: 11411343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
    Tang Y; Osawa H; Onuma H; Nishimiya T; Ochi M; Makino H
    Diabetes; 1999 Sep; 48(9):1830-5. PubMed ID: 10480615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
    Sohda T; Mizuno K; Momose Y; Ikeda H; Fujita T; Meguro K
    J Med Chem; 1992 Jul; 35(14):2617-26. PubMed ID: 1635060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression.
    Hofmann CA; Edwards CW; Hillman RM; Colca JR
    Endocrinology; 1992 Feb; 130(2):735-40. PubMed ID: 1733721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds.
    Momose Y; Meguro K; Ikeda H; Hatanaka C; Oi S; Sohda T
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1440-5. PubMed ID: 1934164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
    Ikeda H; Taketomi S; Sugiyama Y; Shimura Y; Sohda T; Meguro K; Fujita T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):156-62. PubMed ID: 2334455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent.
    Fujita T; Sugiyama Y; Taketomi S; Sohda T; Kawamatsu Y; Iwatsuka H; Suzuoki Z
    Diabetes; 1983 Sep; 32(9):804-10. PubMed ID: 6354788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The development of thiazolidinedione drugs as anti-diabetic agents].
    Kuzuya T
    Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
    Tanis SP; Parker TT; Colca JR; Fisher RM; Kletzein RF
    J Med Chem; 1996 Dec; 39(26):5053-63. PubMed ID: 8978836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
    Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
    Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological effects of a thiazolidinedione derivative, pioglitazone].
    Ikeda H; Sugiyama Y
    Nihon Rinsho; 2001 Nov; 59(11):2191-4. PubMed ID: 11712406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.
    Murase K; Odaka H; Suzuki M; Tayuki N; Ikeda H
    Diabetologia; 1998 Mar; 41(3):257-64. PubMed ID: 9541164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
    Sugiyama Y; Taketomi S; Shimura Y; Ikeda H; Fujita T
    Arzneimittelforschung; 1990 Mar; 40(3):263-7. PubMed ID: 2189419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.
    Hofmann C; Lorenz K; Colca JR
    Endocrinology; 1991 Oct; 129(4):1915-25. PubMed ID: 1915075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.
    Watanabe Y; Nakayama K; Taniuchi N; Horai Y; Kuriyama C; Ueta K; Arakawa K; Senbonmatsu T; Shiotani M
    PLoS One; 2015; 10(1):e0116851. PubMed ID: 25615826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats.
    Sugiyama Y; Shimura Y; Ikeda H
    Arzneimittelforschung; 1990 Apr; 40(4):436-40. PubMed ID: 2192715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
    Yoshimoto T; Naruse M; Nishikawa M; Naruse K; Tanabe A; Seki T; Imaki T; Demura R; Aikawa E; Demura H
    Am J Physiol; 1997 Jun; 272(6 Pt 1):E989-96. PubMed ID: 9227442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD; Campbell LK; Campbell RK
    Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.